Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography

European Urology

Volumn 60, Issue 5, 2011, Pages 935-943

  Rigatti, Patrizio ^a   Suardi, Nazareno ^a   Briganti, Alberto ^a   Da Pozzo, Luigi F ^b   Tutolo, Manuela ^a   Villa, Luca ^a   Gallina, Andrea ^a   Capitanio, Umberto ^a   Abdollah, Firas ^a   Scattoni, Vincenzo ^a   Colombo, Renzo ^a   Freschi, Massimo ^a   Picchio, Maria ^a   Messa, Cristina ^a   Guazzoni, Giorgio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

11C choline PET CT; Biochemical recurrence; Lymph node dissection; Prostate cancer

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIAGNOSTIC IMAGING; FEVER; HUMAN; ILEUS; LUNG EMBOLISM; LYMPH NODE DISSECTION; LYMPHOCELE; LYMPHORRHEA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RETROPERITONEUM; SALVAGE THERAPY; SURVIVAL RATE; URETER INJURY; WOUND DEHISCENCE;

AGED; CHOLINE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PELVIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROPERITONEAL SPACE; RISK ASSESSMENT; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE;

EID: 80053317243     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.07.060     Document Type: Article

References (29)

1. M.N. Simmons, A.J. Stephenson, and E.A. Klein Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy Eur Urol 51 2007 1175 1184 (Pubitemid 46436320)
2. N. Suardi, C.R. Porter, and A.M. Reuther A nomogram predicting long-term biochemical recurrence after radical prostatectomy Cancer 112 2008 1254 1263 (Pubitemid 351429740)
3. S.A. Boorjian, R.H. Thompson, and M.K. Tollefson Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893 899
4. M. Han, A.W. Partin, C.R. Pound, J.I. Epstein, and P.C. Walsh Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555 565 (Pubitemid 32916759)
5. C.R. Pound, A.W. Partin, and M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597 (Pubitemid 29211767)
6. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
7. J. Mohler, R.R. Bahnson, and B. Boston NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2010 162 200
8. H.M. Sandler, and M.A. Eisenberger Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy J Urol 178 2007 S20 S24
9. M. Picchio, A. Briganti, and S. Fanti The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer Eur Urol 59 2011 51 60
10. 11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy Eur Urol 52 2007 423 429 (Pubitemid 46963456)
11. M.C. Schumacher, F.C. Burkhard, G.N. Thalmann, A. Fleischmann, and U.E. Studer Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy Eur Urol 54 2008 344 352
12. A. Briganti, J.R. Karnes, and L.F. Da Pozzo Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270
13. Briganti A, Suardi N, Capogrosso P, et al. Lymphatic spread of nodal metastases in high-risk prostate cancer: the ascending pathway from the pelvis to the retroperitoneum. Prostate. In press. DOI:10.1002/pros.21420.
14. B.H. Bochner, D. Cho, and H.W. Herr Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping J Urol 172 2004 1286 1290 (Pubitemid 39249699)
15. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213 (Pubitemid 38963009)
16. A.L. Hanlon, H. Diratzouian, and G.E. Hanks Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer Int J Radiat Oncol Biol Phys 53 2002 297 303 (Pubitemid 34522096)
17. C. Kwak, S.J. Jeong, M.S. Park, E. Lee, and S.E. Lee Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer J Urol 168 2002 995 1000
18. Park SY, Choi GS, Jun SH, Park JS, Kim HJ. Laparoscopic salvage surgery for recurrent and metachronous colorectal cancer: 15 years' experience in a single center. Surg Endosc. In press.
19. G. Eeson, M. Foo, S. Harrow, G. McGregor, and J. Hay Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment Am J Surg 201 2011 624 629
20. J.H. Yim, W.B. Kim, and E.Y. Kim The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation J Clin Endocrinol Metab 96 2011 2049 2056
21. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
22. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer Eur Urol 44 2003 32 39 (Pubitemid 36741372)
23. B.J. Krause, M. Souvatzoglou, and M. Tuncel The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 2008 18 23 (Pubitemid 350234152)
24. N. Suardi, A. Briganti, A. Salonia, and P. Rigatti Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence Curr Opin Urol 21 2011 237 240
25. L. Rinnab, J. Simon, and R.E. Hautmann [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy World J Urol 27 2009 619 625
26. A. Winter, J. Uphoff, R.P. Henke, and F. Wawroschek First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy Urol Int 84 2010 418 423
27. Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. In press.
28. A. Mattei, F.G. Fuechsel, and N. Bhatta Dhar The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study Eur Urol 53 2008 118 125 (Pubitemid 350166722)
29. C.F. Snyder, K.D. Frick, and A.L. Blackford How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer 116 2010 5391 5399